Healthcare & Medical Devices Global On demand · 24-48h

Global Pulmonary Lobe Forceps Market Strategic Research Report

Global Pulmonary Lobe Forceps Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Pulmonary Lobe Forceps Market
$1852025
5.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Head Width 8mm, Head Width 12mm, Others

By Application: Teaching Hospital, Operating Room, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: B. Braun Melsungen AG, Aesculap (B. Braun), Integra LifeSciences, Stryker Corporation, Zimmer Biomet, Smith & Nephew plc, Johnson & Johnson MedTech, Medtronic plc, CONMED Corporation, Teleflex Incorporated, Karl Storz SE & Co. KG, Richard Wolf GmbH, Erbe Elektromedizin GmbH, Olympus Corporation, HOYA Corporation, Nakanishi Inc., Getinge AB, STILLE AB, Tontarra Medizintechnik GmbH, Sklar Surgical Instruments, Hu-Friedy Group, BD (Becton Dickinson), Medline Industries, Shandong Weigao Orthopaedic Device Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd., Shanghai Shinva Medical Instrument Co., Ltd., Shanghai Medical Instruments (Group) Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 177 pages
Market size 2025
$185
Million USD
Forecast CAGR
5.4%
2025-2032
Forecast 2032
$267.3
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Pulmonary Lobe Forceps market size is predicted to grow from US$ 185 million in 2025 to US$ 275 million in 2032; it is expected to grow at a CAGR of 5.4% from 2026 to 2032.

Pulmonary lobe forceps are specialized surgical instruments used in thoracic surgery for grasping, retracting, and manipulating lung tissue during procedures such as lobectomy, lung cancer resection, and minimally invasive thoracoscopic surgery. They are typically made of high-strength stainless steel or titanium alloys and consist of a handle, a joint mechanism, and serrated or smooth jaws designed to securely hold delicate lung tissue without causing damage. In both open and minimally invasive thoracic procedures, these forceps help surgeons position lung lobes for better visualization and facilitate dissection of vessels and bronchi. Depending on surgical requirements, pulmonary lobe forceps are available in straight, curved, and anatomically adapted designs.

From a market development perspective, pulmonary lobe forceps benefit from the rising global incidence of lung cancer and the rapid advancement of minimally invasive thoracic surgery. Lung cancer remains one of the most prevalent and deadly malignancies worldwide, and surgical resection continues to be a primary treatment option, driving sustained demand for related surgical instruments. The widespread adoption of video-assisted thoracoscopic surgery and robot-assisted thoracic surgery significantly increases the need for precise surgical tools, with pulmonary lobe forceps serving as essential instruments whose demand scales with surgical volume. In addition, the shift toward minimally invasive and enhanced recovery surgical pathways further promotes standardization and high-frequency usage of thoracic instruments. Emerging markets also contribute incremental demand due to improving healthcare infrastructure and increased surgical penetration.

From a market challenge perspective, pulmonary lobe forceps are low-cost, highly standardized surgical instruments with limited product differentiation. Competition is mainly concentrated among major global medical device companies and regional OEM manufacturers. The technical barrier primarily lies in material processing and precision manufacturing rather than innovation, resulting in intense price competition. Furthermore, strict regulatory frameworks in major markets such as the United States and Europe increase entry barriers and compliance costs. Long product life cycles and slow replacement rates mean revenue growth is largely driven by surgical volume rather than product upgrades.

From downstream demand trends, hospital procurement is shifting toward integrated thoracic surgery solutions, combining surgical instruments, energy devices, and endoscopic systems. The rise of minimally invasive and robotic-assisted thoracic surgery increases requirements for ergonomic design and precision instruments. The expansion of ambulatory surgical centers further drives demand for lightweight and efficient tools. In the long term, increasing lung cancer screening and population aging will sustain growth in thoracic surgeries, supporting stable demand for pulmonary lobe forceps.

This report presents a comprehensive overview of the global Pulmonary Lobe Forceps market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Head Width 8mm
  • Head Width 12mm
  • Others

Segment by Structural Design

  • Straight Lobar Forceps
  • Curved Lobar Forceps
  • Angled Thoracic Forceps
  • Atraumatic Forceps

Segment by Material Type

  • Stainless Steel Forceps
  • Titanium Alloy Forceps
  • Coated Surface Forceps
  • Single-use Polymer Forceps

Segment by Application

  • Teaching Hospital
  • Operating Room
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pulmonary Lobe Forceps market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Teaching Hospital, Operating Room, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Pulmonary Lobe Forceps Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$185
2025
Forecast
$267.3
2032
CAGR
5.4%
2025–2032
Regions
5
global
Key companies
B. Braun Melsungen AGAesculap (B. Braun)Integra LifeSciencesStryker CorporationZimmer BiometSmith & Nephew plcJohnson & Johnson MedTechMedtronic plc
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Head Width 8mmHead Width 12mmOthers
By Application
Teaching HospitalOperating RoomOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Head Width 8mm
  • 3.1.3 Head Width 12mm
  • 3.1.4 Others
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Teaching Hospital
  • 4.1.3 Operating Room
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 B. Braun Melsungen AG
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Aesculap (B. Braun)
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Integra LifeSciences
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Stryker Corporation
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Zimmer Biomet
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Smith & Nephew plc
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Johnson & Johnson MedTech
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Medtronic plc
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 CONMED Corporation
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Teleflex Incorporated
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Karl Storz SE & Co. KG
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Richard Wolf GmbH
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Erbe Elektromedizin GmbH
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Olympus Corporation
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 HOYA Corporation
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Nakanishi Inc.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Getinge AB
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 STILLE AB
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Tontarra Medizintechnik GmbH
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Sklar Surgical Instruments
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Hu-Friedy Group
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 BD (Becton Dickinson)
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Medline Industries
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Shandong Weigao Orthopaedic Device Co., Ltd.
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Lepu Medical Technology (Beijing) Co., Ltd.
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Shanghai Shinva Medical Instrument Co., Ltd.
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 Shanghai Medical Instruments (Group) Co., Ltd.
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Pulmonary Lobe Forceps market?
The global Pulmonary Lobe Forceps market is estimated at US$ 185 million in 2025 (base year) and is projected to reach US$ 275 million by 2032.
What is the forecast CAGR for the Pulmonary Lobe Forceps market?
The market is expected to grow at a CAGR of 5.4% from 2026 to 2032, expanding from US$ 185 million in 2025 to US$ 275 million in 2032, roughly 1.5 times its base-year value.
What is Pulmonary Lobe Forceps?
Pulmonary lobe forceps are specialized surgical instruments used in thoracic surgery for grasping, retracting, and manipulating lung tissue during procedures such as lobectomy, lung cancer resection, and minimally invasive thoracoscopic surgery. They are typically made of high-strength stainless steel or titanium alloys and consist of a handle, a joint mechanism, and serrated or smooth jaws designed to securely hold delicate lung tissue without causing damage.
How is the Pulmonary Lobe Forceps market segmented by type?
By type, the market is segmented into Head Width 8mm, Head Width 12mm and Others.
What are the key applications of Pulmonary Lobe Forceps?
Key applications covered include Teaching Hospital, Operating Room and Others.
Which companies are profiled in the Pulmonary Lobe Forceps market report?
Key players profiled include B. Braun Melsungen AG, Aesculap (B. Braun), Integra LifeSciences, Stryker Corporation, Zimmer Biomet, Smith & Nephew plc, Johnson & Johnson MedTech and Medtronic plc, among 27 companies covered in total.
What geographies does the Pulmonary Lobe Forceps market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Pulmonary Lobe Forceps?
Lung cancer remains one of the most prevalent and deadly malignancies worldwide, and surgical resection continues to be a primary treatment option, driving sustained demand for related surgical instruments.
What are the main risks and barriers in the Pulmonary Lobe Forceps market?
From a market challenge perspective, pulmonary lobe forceps are low-cost, highly standardized surgical instruments with limited product differentiation.
Who should buy the Pulmonary Lobe Forceps market report?
The report is intended for manufacturers and solution providers, distributors and end users in Teaching Hospital, Operating Room and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Pulmonary Lobe Forceps market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.